# Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS)

> **NCT03088293** · PHASE3 · WITHDRAWN · sponsor: **Hospices Civils de Lyon**

## Conditions studied

- Idiopathic Refractory Scleritis

## Interventions

- **DRUG:** Infliximab
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03088293
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-06-11
- **Primary completion:** 2023-10
- **Final completion:** 2024-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** recruiting difficulties
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03088293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03088293, "Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03088293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*